These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

81 related articles for article (PubMed ID: 3030547)

  • 1. High-dose cytarabine in small cell lung cancer.
    Osborne RJ; Clark PI; Slevin ML; Wrigley PF
    Cancer Treat Rep; 1987 Apr; 71(4):417-8. PubMed ID: 3030547
    [No Abstract]   [Full Text] [Related]  

  • 2. Cytarabine: an inactive drug for extensive-stage small cell lung cancer.
    Stuart-Harris R; Bishop J; Raghavan D; Gianoutsos P; Lee J; Hillcoat B; Fox R
    Cancer Treat Rep; 1986 Feb; 70(2):303-4. PubMed ID: 3004728
    [No Abstract]   [Full Text] [Related]  

  • 3. Acute cerebellar toxicity after high-dose cytarabine associated with CNS accumulation of its metabolite, uracil arabinoside.
    Lopez JA; Agarwal RP
    Cancer Treat Rep; 1984 Oct; 68(10):1309-10. PubMed ID: 6098367
    [No Abstract]   [Full Text] [Related]  

  • 4. Overview of paclitaxel (Taxol) in advanced lung cancer.
    Ettinger DS
    Semin Oncol; 1993 Aug; 20(4 Suppl 3):46-9. PubMed ID: 8102017
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A randomized controlled trial comparing intrathecal sustained-release cytarabine (DepoCyt) to intrathecal methotrexate in patients with neoplastic meningitis from solid tumors.
    Glantz MJ; Jaeckle KA; Chamberlain MC; Phuphanich S; Recht L; Swinnen LJ; Maria B; LaFollette S; Schumann GB; Cole BF; Howell SB
    Clin Cancer Res; 1999 Nov; 5(11):3394-402. PubMed ID: 10589750
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Combination chemotherapy with VP-16 in the treatment of lung cancer and malignant lymphoma].
    Hosomi Y; Shibuya M
    Gan To Kagaku Ryoho; 2001 Oct; 28(10):1352-6. PubMed ID: 11681241
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Vepeside (VP-16-213) in the treatment of bronchopulmonary cancer (preliminary data)].
    Anastasatu C; Burnea D; Iancovici O; Avramescu D; Burnea-Cornetti R
    Rev Ig Bacteriol Virusol Parazitol Epidemiol Pneumoftiziol Pneumoftiziol; 1987; 36(1):41-56. PubMed ID: 3033800
    [No Abstract]   [Full Text] [Related]  

  • 8. High-dose etoposide therapy for extensive small cell lung cancer: a Cancer and Leukemia Group B Study.
    Luikart SD; Propert KJ; Modeas CR; Green MR; Perry MC
    Cancer Treat Rep; 1987 May; 71(5):533-4. PubMed ID: 3032434
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Role of carboplatin in the treatment of lung cancer].
    Bréchot JM
    Bull Cancer; 2000 Aug; 87 Spec No():34-9. PubMed ID: 11082721
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A phase II trial of m-AMSA in patients with small-cell lung cancer.
    Natale RB; Gralla RJ; Wittes RE
    Cancer Clin Trials; 1981; 4(4):393-5. PubMed ID: 6274533
    [TBL] [Abstract][Full Text] [Related]  

  • 11. "Ifosfamide plus N-acetylcysteine in the treatment of small cell and non-small cell carcinoma of the lung: a Southeastern Cancer Study Group Trial".
    Holoye PY
    Cancer Treat Rep; 1987 Apr; 71(4):431-2. PubMed ID: 3030548
    [No Abstract]   [Full Text] [Related]  

  • 12. High-dose etoposide as single-agent chemotherapy for small cell carcinoma of the lung.
    Wolff SN; Johnson DH; Hande KR; Hainsworth JD; Greco FA
    Cancer Treat Rep; 1983 Oct; 67(10):957-8. PubMed ID: 6313189
    [No Abstract]   [Full Text] [Related]  

  • 13. Clinical trials referral resource. Small-cell lung cancer.
    Cheson BD; Feigal EG; Phillips PH
    Oncology (Williston Park); 1993 Oct; 7(10):43-7. PubMed ID: 8251307
    [No Abstract]   [Full Text] [Related]  

  • 14. Phase I clinical evaluation of cytarabine and cisplatin in patients with advanced cancer.
    Schilsky RL; Muscato JJ; Muscato MS; Perry MC
    Cancer Treat Rep; 1984 Sep; 68(9):1097-102. PubMed ID: 6541094
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Angiogenesis inhibitors in the treatment of small cell and non-small cell lung cancer.
    Blackhall FH; Shepherd FA
    Hematol Oncol Clin North Am; 2004 Oct; 18(5):1121-41, ix. PubMed ID: 15474338
    [TBL] [Abstract][Full Text] [Related]  

  • 16. An evaluation of low-dose cisplatin as part of combined modality therapy of limited small cell lung cancer.
    Eagan RT; Lee RE; Frytak S; Fleming TR; Ingle JN; Creagan ET; Nichols WC; Kvols LK; Coles DT
    Cancer Clin Trials; 1981; 4(3):267-71. PubMed ID: 6269770
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [MACC plus thymostimulin (TP-1 Serono) therapy of small cell bronchogenic carcinoma. Clinico-immunologic evaluation of the results of a randomized trial].
    Salvati F; Pallotta G; Antilli A; Nunziati F; De Marinis F; Lucchesi M
    G Ital Chemioter; 1984; 31(1-2):185-9. PubMed ID: 6088341
    [No Abstract]   [Full Text] [Related]  

  • 18. [Treatment of oat cell metastazing bronchial carcinoma with isofosfamide. Results of a prospective randomized study].
    Kokron O
    Osterr Z Onkol; 1974; (5-6):123-7. PubMed ID: 4377798
    [No Abstract]   [Full Text] [Related]  

  • 19. Imatinib for small cell lung cancer, aiming for a target in vivo.
    Johnson BE
    Clin Cancer Res; 2004 May; 10(10):3235-6. PubMed ID: 15161675
    [No Abstract]   [Full Text] [Related]  

  • 20. Phase II clinical trial with bisantrene in patients with advanced refractory small cell lung cancer.
    Myers JW; Von Hoff DD; Clark GM; Coltman CA
    Cancer Treat Rep; 1984 Jun; 68(6):927-8. PubMed ID: 6329511
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 5.